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Cardiovascular disease, including coronary artery disease (CAD), 
is the major cause of morbidity and mortality for individuals 
with diabetes and the largest contributor to the direct and in-
direct costs of diabetes [1,2]. Patients with diabetes are affected 
by other risk factors such as dyslipidemia, hypertension, pro-
thrombic and proinflammatory factors, and therefore athero-
sclerosis in type 2 diabetes mellitus is often accelerated [3]. 
However, the pathophysiologic mechanisms responsible for 
the substantially increased risk for CAD in adult type 2 diabe-
tes remain unclear. Inflammation plays a pivotal role in ath-
erosclerosis, and inflammatory markers such as C-reactive 
protein, platelet-derived growth factor, transforming growth 
factor-beta, and granulocyte-macrophage colony stimulating 
factor may help clinicians to identify high risk patients [4,5]. 
In many previous studies, the association between inflamma-
tory markers and coronary atherosclerosis was weak and most-
ly explained by the concomitant burden of CAD risk factors. 
  Cystatin C is a novel endogenous marker of kidney function 
that may be more sensitive than inflammatory markers for de-
tection of mild to moderate decrements in glomerular filtra-
tion rate [6]. However, few data exist on the relationship be-
tween serum cystatin C level and cardiovascular disease in di-
abetic patients with or without diabetic nephropathy. Maahs et 
al. [7] reported a significant relationship between serum cysta-
tin C level and CAD in type 1 diabetic patients, but they as-
sessed surrogate markers of CAD rather than CAD events or 
death and more importantly did not consider urinary albumin 
excretion.
  In contrast with previous studies, Kim et al. [8] reported that 
they found no association between serum cystatin C level and 
CAD in diabetic patients and that serum cystatin C levels were 
significantly higher in patients with diabetic nephropathy than 
in patients without both in CAD patients and non-CAD pa-
tients. However, the study used a retrospective case-control de-
sign, the sample was relatively small, and they did not evaluate 
the relationship between cystatin C levels and other markers 
(inflammatory, structural, and functional), body mass index 
(BMI) or other variables. Recently, Maahs et al. [9] investigated 
whether the relationship between cystatin C and progression 
of CAD differed between individuals with type 1 diabetes and 
without diabetes. In results, the univariate associations of cys-
tatin C to CAD progression were similar in type 1 diabetic pa-
tients and without diabetes mellitus. The association of cysta-
tin C to progression of CAD differed in the expected direction 
(increased cystatin C as a biomarker of worsening renal func-
tion associated with CAD progression) by type 1 diabetes sta-
tus (P = 0.01) after adjustment for other risk factors of cardio-
vascular disease. Therefore, Maahs et al. [7] suggested, which a 
complex relationship exists among cystatin C, BMI, and CAD 
progression, which requires further study. 
  I appreciate the devotion of study investigators, who are 
conducting important research about the relationship between 
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cystatin C and diabetes, and hope that they will continue to do 
so in the future.
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